Kos preclinical study shows Reverse-D4F may reduce the progression of atherosclerosis

By Angela McDaniels

Seattle, Nov. 14 - Kos Pharmaceuticals Inc. said its Reverse-D4F reduced the atherosclerotic lesion area in a preclinical animal model by 46%, making it at least as effective as D-4F and more effective than L-4F mimetic peptide or placebo in slowing the progression of atherosclerosis in mice.

The study utilized apolipoprotein E knockout mice, a well-established animal model simulating human atherosclerosis, the company said.

"As one of the fastest growing pharmaceutical companies in the USA, we see tremendous opportunity to sustain growth and build on our leadership position in the HDL-C market by leveraging our heritage and our extensive cardiovascular knowledge to create potential new chemical entities through our sponsored research programs," Kos president and chief executive officer Adrian Adams said in a company news release.

"This is part of a synergistic strategy to broaden our research and development efforts with measured, cost-effective investments in our core therapy areas."

The results were presented at the 2005 Scientific Sessions of the American Heart Association meeting in Dallas.

Reverse-D4F was developed on behalf of Kos through its research agreement with Boston-based Arisaph Pharmaceuticals, formerly known as Triad Pharmaceuticals Inc.

Kos Pharmaceuticals develops prescription pharmaceutical products for the treatment of chronic cardiovascular and respiratory diseases and is based in Miami.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.